tiprankstipranks
AstraZeneca PLC (AZN)
NYSE:AZN
US Market
Want to see AZN full AI Analyst Report?

AstraZeneca (AZN) Stock Forecast & Price Target

390 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Strong Buy
15Ratings
Strong Buy
13 Buy
1 Hold
1 Sell
Based on 15 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

$222.35
▲(8.57% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $222.35 with a high forecast of $277.16 and a low forecast of $152.77. The average price target represents a 8.57% change from the last price of $204.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"136":"$136","207":"$207","278":"$278","171.5":"$171.5","242.5":"$242.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":277.15631,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$277.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":222.35441076319842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$222.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":152.773966,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$152.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[136,171.5,207,242.5,278],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,206.60894692307693,212.48789384615384,218.36684076923078,224.2457876923077,230.12473461538463,236.00368153846154,241.88262846153847,247.76157538461538,253.64052230769232,259.51946923076923,265.39841615384614,271.2773630769231,{"y":277.15631,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,202.39341621255372,204.05683242510744,205.72024863766117,207.3836648502149,209.04708106276863,210.71049727532233,212.37391348787605,214.03732970042978,215.7007459129835,217.36416212553723,219.02757833809096,220.6909945506447,{"y":222.35441076319842,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,197.0410743076923,193.3521486153846,189.66322292307692,185.97429723076922,182.28537153846153,178.59644584615384,174.90752015384615,171.21859446153846,167.52966876923077,163.84074307692308,160.15181738461538,156.4628916923077,{"y":152.773966,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":145.565,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.204,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.042,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.956,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.453,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.864,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.225,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.474,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.674,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.73,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.73,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$277.16Average Price Target$222.35Lowest Price Target$152.77
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DZ BANK AG Analyst forecast on AZN
DZ BANK AG
DZ BANK AG
Buy
Upgraded
04/29/26
Positive Report for AstraZeneca (AZN) from DZ BANK AG
Barclays
$223.08
Buy
8.92%
Upside
Reiterated
04/29/26
AstraZeneca (AZN) Gets a Buy from Barclays
Deutsche Bank  Analyst forecast on AZN
Deutsche Bank
Deutsche Bank
$155.48
Sell
-24.08%
Downside
Reiterated
04/28/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
J.P. Morgan Analyst forecast on AZN
J.P. Morgan
J.P. Morgan
$216.32
Buy
5.62%
Upside
Reiterated
04/21/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on AZN
Goldman Sachs
Goldman Sachs
$224.43
Buy
9.58%
Upside
Reiterated
04/21/26
BUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
Morgan Stanley Analyst forecast on AZN
Morgan Stanley
Morgan Stanley
$223.08
Buy
8.92%
Upside
Reiterated
04/13/26
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
UBS
$237.95
Buy
16.19%
Upside
Reiterated
04/10/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Citi
$229.84$243.36
Buy
18.83%
Upside
Reiterated
04/10/26
AstraZeneca (AZN) Gets a Buy from Citi
Jefferies
$243.36
Buy
18.83%
Upside
Reiterated
04/10/26
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on AZN
Bank of America Securities
Bank of America Securities
$223.08
Buy
8.92%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Guggenheim
$216.32$223.08
Buy
8.92%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on AZN
TD Cowen
TD Cowen
$240
Buy
17.19%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on AZN
Bernstein
Bernstein
$14.37$277.16
Buy
35.33%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on AZN
Berenberg Bank
Berenberg Bank
$229.84
Buy
12.23%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Kepler Capital  Analyst forecast on AZN
Kepler Capital
Kepler Capital
$152.77
Hold
-25.40%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DZ BANK AG Analyst forecast on AZN
DZ BANK AG
DZ BANK AG
Buy
Upgraded
04/29/26
Positive Report for AstraZeneca (AZN) from DZ BANK AG
Barclays
$223.08
Buy
8.92%
Upside
Reiterated
04/29/26
AstraZeneca (AZN) Gets a Buy from Barclays
Deutsche Bank  Analyst forecast on AZN
Deutsche Bank
Deutsche Bank
$155.48
Sell
-24.08%
Downside
Reiterated
04/28/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
J.P. Morgan Analyst forecast on AZN
J.P. Morgan
J.P. Morgan
$216.32
Buy
5.62%
Upside
Reiterated
04/21/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on AZN
Goldman Sachs
Goldman Sachs
$224.43
Buy
9.58%
Upside
Reiterated
04/21/26
BUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
Morgan Stanley Analyst forecast on AZN
Morgan Stanley
Morgan Stanley
$223.08
Buy
8.92%
Upside
Reiterated
04/13/26
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
UBS
$237.95
Buy
16.19%
Upside
Reiterated
04/10/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Citi
$229.84$243.36
Buy
18.83%
Upside
Reiterated
04/10/26
AstraZeneca (AZN) Gets a Buy from Citi
Jefferies
$243.36
Buy
18.83%
Upside
Reiterated
04/10/26
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on AZN
Bank of America Securities
Bank of America Securities
$223.08
Buy
8.92%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Guggenheim
$216.32$223.08
Buy
8.92%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on AZN
TD Cowen
TD Cowen
$240
Buy
17.19%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on AZN
Bernstein
Bernstein
$14.37$277.16
Buy
35.33%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on AZN
Berenberg Bank
Berenberg Bank
$229.84
Buy
12.23%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
Kepler Capital  Analyst forecast on AZN
Kepler Capital
Kepler Capital
$152.77
Hold
-25.40%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
xxx
Success Rate
14/22 ratings generated profit
64%
Average Return
+3.70%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +3.70% per trade.
1 Year
Success Rate
35/39 ratings generated profit
90%
Average Return
+16.77%
Copying Matthew Weston's trades and holding each position for 1 Year would result in 89.74% of your transactions generating a profit, with an average return of +16.77% per trade.
2 Years
xxx
Success Rate
35/39 ratings generated profit
90%
Average Return
+22.79%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.74% of your transactions generating a profit, with an average return of +22.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
34
29
29
41
41
Hold
2
1
2
2
2
Sell
6
5
5
7
7
Strong Sell
0
0
0
0
0
total
42
35
36
50
50
In the current month, AZN has received 41 Buy Ratings, 2 Hold Ratings, and 7 Sell Ratings. AZN average Analyst price target in the past 3 months is 222.35.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

The previous quarter’s earnings for AZN were $1.99.
The previous quarter’s earnings for AZN were $1.99.

AZN Sales Forecast

The previous quarter’s earnings for AZN were $15.29B.
The previous quarter’s earnings for AZN were $15.29B.

AZN Stock Forecast FAQ

What is AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 222.35.
    What is AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 8.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AZN a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s price target?
            The average price target for AstraZeneca PLC is 222.35. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $277.16 ,the lowest forecast is $152.77. The average price target represents 8.57% Increase from the current price of $204.8.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AZN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.